| 155例β-内酰胺酶抑制剂复合制剂致不良反应文献分析 |
| |
| 引用本文： | 吴聪菊. 155例β-内酰胺酶抑制剂复合制剂致不良反应文献分析[J]. 中国药房, 2008, 19(32): 2537-2538 |
| |
| 作者姓名： | 吴聪菊 |
| |
| 作者单位： | 首都医科大学大兴医院药剂科 |
| |
| 摘 要： | 目的:探讨β-内酰胺酶抑制剂复合制剂所致不良反应发生的一般规律和特点。方法:利用CHKD期刊全文数据库,检索到1996年1月～2008年1月中文医药卫生期刊发表的有关应用β-内酰胺酶抑制剂复合制剂出现的不良反应文献141篇,共155例,并进行分析整理。结果:155例不良反应中,含舒巴坦复合制剂引起的不良反应居第1位,共127例(占81.94%);最多的是全身性损害,共66例(占42.58%),其中最突出的是过敏性休克;有9例引起死亡。结论:应注重合理使用β-内酰胺酶抑制剂复合制剂,并重视ADR的监测工作,以减少或避免ADR的发生。
|
| 关 键 词： | β-内酰胺酶抑制剂 药品不良反应 合理用药 分析 |
Adverse Drug Reactions Induced by β- lactamase Inhibitor: Analysis of 155 Cases |
| |
| WU Cong-ju. Adverse Drug Reactions Induced by β- lactamase Inhibitor: Analysis of 155 Cases[J]. China Pharmacy, 2008, 19(32): 2537-2538 |
| |
| Authors: | WU Cong-ju |
| |
| Affiliation: | WU Cong-ju(Dept. of Pharmacy, The Affiliated Daxing Hospital of Capital Medical University, Beijing 102600, China) |
| |
| Abstract: | OBJECTIVE： To explore the general pattern and the characteristics of the adverse drug reactions （ADR） induced by β- lactamase inhibitor. METHODS： 155 ADR cases induced by β- laetamase inhibitor reported in 141 articles in the domestic periodicals between Jan. 1996 and Jan. 2008 retrieved from CHKD full - text data base were analyzed respectively. RESULTS： Among the total 155 ADR cases, 81.94% （127 cases） were induced by sulbactam-contained β- lactamase inhibitor. Systemic lesion was the most common manifestation of ADR, accounting for 42.58% （66 cases） . The most serious manifestation of ADR was allergic shock, and death occurred in 9 cases. CONCLUSION ： It is advisable to promote rational use of β- lactamase inhibitor and strengthen ADR monitoring so as to reduce or avoid the occurrence of ADR. |
| |
| Keywords: | β- lactamase inhibitor Adverse drug reaction Rational administration Analysis |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
